CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER – Trademark Portfolio
Entity Type: 03
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include MESOGE. The owner is based in NEWARK, CA.
39899 BALENTINE DR 315
NEWARK, CA 94560
Showing of trademarks Trademarks
Trademark Classifications
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER have?
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.
What trademark classes does CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER file in?
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER's most well-known trademarks?
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER's registered trademark portfolio includes well-known marks such as MESOGE. These are among 1 currently registered trademark in the portfolio.
What is CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER's trademark registration success rate?
CALIFORNIA REPRODUCTIVE ASSISTED PREGNANCY MEDICAL CENTER has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.